A phase 2b, randomized, multicenter, active-controlled, open-label study to evaluate the efficacy and safety of Albuferon (recombinant human albumin-interferon alfa fusion protein) in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 1.

Trial Profile

A phase 2b, randomized, multicenter, active-controlled, open-label study to evaluate the efficacy and safety of Albuferon (recombinant human albumin-interferon alfa fusion protein) in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 1.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 27 Apr 2011 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov.
    • 22 May 2008 Results were reported at the Digestive Disease Week 2008.
    • 06 Nov 2007 Quality-of-life results at 12 and 24 weeks presented at AASLD 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top